Researchers dig into past records to find clues for melanoma immunotherapy success
NCT ID NCT07302607
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study reviews medical records of 221 people with advanced melanoma who received immunotherapy between 2013 and 2021. The goal is to find new factors that predict which patients achieve a complete and lasting response. Participants must be 18 or older and have received treatment at Strasbourg University Hospitals. The study does not involve new treatments or direct benefits to participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service de dermatologie - Réanimation - CHU de Strasbourg - France
RECRUITINGStrasbourg, 67091, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of immune boosters revive cancer treatment?
- Could a personal coach at home boost energy for cancer patients?
- Morning vs. afternoon: could the clock boost immunotherapy against melanoma?
- Could a common vaccine supercharge immunotherapy against melanoma?
- Engineered immune cells take aim at Hard-to-Treat cancers
- New drug cocktail targets rare, aggressive melanoma